The final report for the Relative Effectiveness Assessment OTCA 25 “Stereotactic body radiation therapy (SBRT) for the treatment of lung, prostate and liver cancer”, is now available for access.
The aim of this HTA was to assess if the use of SBRT is more effective and safer compared to radiotherapy (RT), surgery, or surgery and conventional RT in adult patients divided into six subgroups or populations: patients with localised primary cancers (stage I or II) in (i) bronchus and lung (non-small cell lung cancer), (ii) prostate or (iii) liver, or those patients with tumours with oligometastases (stage IV) including at least one to (iv) bronchus and lung, (v) prostate or (vi) liver.
This HTA provides information on direct comparisons assessed by randomized controlled trials or nonrandomized comparative studies, considering both their effects and information on quality of the related evidence.
Please access all documentation for OTCA25 at the following links:
OTCA25 Final Report
OTCA25 Comments from External Experts and Manufacturers
OTCA25 Final Project Plan
OTCA25 Comments from External Experts
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.